ozempic fda - Search News

FDA announces end to Wegovy and Ozempic drug shortages

Drug compounders sue US FDA over removal of Wegovy, Ozempic from shortage list

Drug compounders on Monday sued the U.S. Food and Drug Administration over its decision last week to remove Novo Nordisk's weight loss and diabetes drugs Wegovy and Ozempic from its shortage list, a move that will sharply curtail the compounders' ability to sell cheaper versions of the drugs.

CNN on MSN · 3d

Ozempic and Wegovy are no longer in shortage, FDA says

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration said on Friday.

The Washington Post on MSN · 3d

FDA says Ozempic shortage is over, chilling boom in off-brand versions

The FDA has now resolved the shortages of Novo Nordisk’s and Eli Lilly’s blockbuster weight-loss drugs, which could spell the end to the booming market for cheaper versions made by pharmacies.

Becker's Hospital Review · 6h

FDA sets deadline to end sales of Ozempic, Wegovy copycats

Semaglutide — the key ingredient in Ozempic and Wegovy — had been in shortage since 2022. Now that supply has stabilized, state-licensed compounding pharmacies and physicians must stop selling compounded semaglutide by April 22, while outsourcing facilities have until May 22 to cease production and distribution.

USA TODAY on MSN · 3d

Generic Wegovy, Ozempic compounds may become harder to get as FDA removes drug from shortage list

Compounding pharmacies producing cheaper semaglutide products have been given notice they will soon have to stop, as the drug is no longer on the FDA shortage list.

Yahoo · 1d

FDA says Ozempic, Wegovy are not in short supply anymore, which could impact prices

The U.S. Food and Drug Administration said Ozempic and Wegovy, the popular GLP-1 drugs for diabetes and weight loss, are no longer in short supply. CBS News New York reporter Ali Bauman reports on whether the supply change could lead to consumers paying more.

The Hill on MSN · 3d

Ozempic and Wegovy officially moved off FDA’s drug shortage list

Ozempic and Wegovy, the widely popular forms of semaglutide sold to treat diabetes and obesity, have officially been removed from the Food and Drug Administration’s (FDA) drug shortage list

CBS News on MSN · 1d

FDA declares end to Wegovy and Ozempic shortage

The agency first declared a shortage of semaglutide, the main ingredient used to make Ozempic and Wegovy, in 2022.

MarketWatch · 3d

FDA says Ozempic and Wegovy shortage is ending. That’s bad news for this wellness stock.

We will continue to offer access to personalized treatments as allowed by law to meet patient needs,” Hims & Hers CEO said.

Investopedia on MSN · 3d

Hims & Hers Stock Drops as FDA Says Ozempic and Wegovy No Longer in Short Supply

Key Takeaways Hims & Hers Health shares swooned after the Food & Drug Administration said the active ingredient in Ozempic and Wegovy is no longer in short supply.The company makes compounded versions of weight-loss drugs under an FDA rule that applies when the originals are difficult to obtain.

Scripps News on MSN · 2d

FDA announces end to Wegovy and Ozempic drug shortages, but it could mean higher prices

The FDA has announced that the shortage of Wegovy and Ozempic, medications used for weight loss and diabetes management, is over.

Yearslong shortage of popular weight-loss and diabetes drugs resolved, FDA says

Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of obesity ...

devdiscourse51m

Legal Battle Over Semaglutide Supply: Compounders vs FDA

Compounders have filed a lawsuit against the FDA challenging its decision to remove Novo Nordisk's Wegovy and Ozempic from the shortage list. The lawsuit claims the FDA's actions are arbitrary, ...

ScienceAlert on MSN3d

Ozempic Literally Came From a Monster – And It's Not Alone

The toxic bite of a Gila monster can kill a human, but a specific ingredient in the cocktail of the lizard's venom is the ...

Novo Nordisk’s OZEMPIC Approval Heat Up the Chronic Kidney Disease Therapeutic Market | DelveInsight

The FDA’s recent approval of OZEMPIC highlights the expanding use of GLP-1 drugs beyond diabetes and weight management. Novo Nordisk’s blockbuster medication has gained another label expansion, now ...